Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price raised by equities research analysts at Scotiabank from $177.00 to $200.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has a “sector outperform” rating on the biopharmaceutical company’s stock. Scotiabank‘s price target would suggest a potential upside of 17.18% from the stock’s current price.
A number of other equities analysts also recently issued reports on the company. Morgan Stanley increased their price objective on Gilead Sciences from $163.00 to $183.00 and gave the stock an “overweight” rating in a report on Friday. Royal Bank Of Canada boosted their price target on Gilead Sciences from $126.00 to $131.00 and gave the company a “sector perform” rating in a report on Friday. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Cantor Fitzgerald lifted their target price on Gilead Sciences from $155.00 to $175.00 and gave the stock an “overweight” rating in a report on Friday. Finally, HSBC raised their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $167.59.
Check Out Our Latest Research Report on Gilead Sciences
Gilead Sciences Stock Performance
Shares of NASDAQ:GILD traded up $5.07 during midday trading on Friday, reaching $170.68. The company had a trading volume of 11,255,218 shares, compared to its average volume of 6,798,897. The company’s 50 day moving average price is $150.33 and its 200 day moving average price is $139.55. Gilead Sciences has a 52-week low of $114.02 and a 52-week high of $175.65. The stock has a market cap of $211.63 billion, a P/E ratio of -63.93 and a beta of 0.31. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $8.30 billion during the quarter, compared to analyst estimates of $7.81 billion. During the same quarter last year, the business earned $2.47 earnings per share. The company’s quarterly revenue was up 6.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Gilead Sciences will post -0.48 EPS for the current fiscal year.
Insider Buying and Selling
In related news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the sale, the insider owned 113,684 shares in the company, valued at approximately $17,759,714.48. This trade represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the sale, the director directly owned 10,066 shares in the company, valued at $1,459,771.32. This represents a 33.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 111,000 shares of company stock valued at $15,877,860 in the last quarter. Corporate insiders own 0.30% of the company’s stock.
Hedge Funds Weigh In On Gilead Sciences
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Gilead Sciences in the 2nd quarter worth about $15,393,785,000. State Street Corp lifted its holdings in shares of Gilead Sciences by 2.3% during the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after buying an additional 1,357,967 shares during the last quarter. Amundi raised its position in shares of Gilead Sciences by 10.7% in the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after purchasing an additional 1,018,976 shares during the period. Legal & General Group Plc acquired a new stake in Gilead Sciences in the 2nd quarter worth $1,316,606,000. Finally, Deutsche Bank AG acquired a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $918,387,000. 83.67% of the stock is owned by institutional investors and hedge funds.
Gilead Sciences News Roundup
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Gilead reported third-quarter adjusted EPS of $2.55, well above the $2.19 consensus estimate, while revenue reached $8.3 billion versus expectations of $7.81 billion. Revenue increased 6.8% year over year, and the company raised its 2026 product-sales outlook to $31.0 billion-$31.3 billion from $30.1 billion-$30.4 billion. Gilead Beats Q3 Earnings on HIV Strength and Trodelvy Sales Growth
- Positive Sentiment: The core business, excluding Veklury, grew 16%—Gilead’s strongest growth in more than a decade. Biktarvy and the broader HIV franchise remained the primary growth engine, while Trodelvy sales rose 41.7% to $506 million and Livdelzi also contributed. Gilead Q3 2026 Earnings Call Transcript
- Positive Sentiment: Analysts raised their targets following the results: Needham to $200, Wells Fargo to $190, Morgan Stanley to $183 and Truist to $181. These revisions indicate improved confidence in near-term earnings momentum. Analysts Increase Forecasts After Upbeat Q3 Results
- Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to $3.28 annually and a yield of approximately 1.9%. The company also secured Canadian reimbursement for Livdelzi, potentially broadening access, but agreed to a $45 million Texas settlement related to alleged unlawful provider incentives.
- Negative Sentiment: Longer-term concerns remain. Medicare price negotiations are expected to reduce Biktarvy’s price by about 38% beginning in 2028, potentially cutting annual revenue by roughly $1.5 billion. Analysts also note that recent HIV growth benefited from inventory and favorable channel timing, while oncology and immunology remain less established and the 2026 EPS outlook was reduced. Gilead Q3 Earnings Call Highlights and Pricing Risks
About Gilead Sciences
Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.
Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.
Featured Articles
- Five stocks we like better than Gilead Sciences
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
